Silicon Investor (SI) -- The First Internet Community

STOCKTALK

We've detected that you're using an ad content blocking browser plug-in or feature. Ads provide a critical source of revenue to the continued operation of Silicon Investor. We ask that you disable ad blocking while on Silicon Investor in the best interests of our community. If you are not using an ad blocker but are still receiving this message, make sure your browser's tracking protection is set to the 'standard' level.

Biotech / Medical : Transkaryotic(tktx) -- Ignore unavailable to you. Want to Upgrade?

To: Souze who wrote (27)	3/29/2000 3:24:00 PM
From: Souze	Respond to of 122

RESEARCH ALERT - Amgen, Transkaryotic reiterated NEW YORK, March 29 (Reuters) - Deutsche Banc Alex. Brown reiterated a strong buy rating on biotechnology company Amgen Inc. (NASDAQ:AMGN) and a market perform rating on Transkaryotic Therapies Inc. (NASDAQ:TKTX). -- Amgen and Transkaryotic are in a patent dispute over Amgen's patents for blockbuster drug Epogen. -- The drug, for kidney dialysis patients with anemia, is Amgen's lead product, with annual sales of about $1.7 billion. -- Deutsche Banc Alex. Brown analyst Dennis Harp said the judge in a pre-trial patent hearing earlier this week drew conclusions which favored Amgen. -- "We believe the probability is increased that Judge Young may grant, in part, Amgen's motion for summary judgment of infringment," Harp wrote in a research note. -- "We believe, based on the advice of outside patent experts, that Amgen will ultimately prevail in the litigation," he wrote. -- Amgen claims Cambridge, Mass.-based Transkaryotic has infringed its patent, while Transkaryotic is charging Amgen with misconduct in obtaining the patent. Amgen shares was off 3/4 to 62-1/16 in afternoon Nasdaq trade, while Transkaryotic shares fell 4-1/2 to 57. david.brinkerhoff@reuters.com)) Copyright 2000, Reuters News Service